COPPS.

Methods	Drug name: acebilustat, camostat Trial design: pragmatic, multi‐arm, adaptive, phase 2, blinded, randomised, placebo‐controlled platform trial Identifiers: NCT04662086 Target sample size: 240 participants Planned completion date: March 2022
Participants	Setting Outpatient USA Eligibility criteria Inclusion criteria Outpatient setting Age ≥ 18 years and ≤ 80 years at the time of the assessment Able and willing to understand the study, adhere to all study procedures, and provide written informed consent Initial diagnosis of COVID‐19 disease as defined by an FDA‐cleared molecular diagnostic assay positive for SARS‐CoV‐2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent At baseline, at least two symptoms should have moderate or higher severity score on the COVID Outpatient Symptom Scale (COSS) Additional inclusion criteria may pertain to specific drugs as described in study‐specific protocols Exclusion criteria At screening, the participant needs to be admitted to the hospital or is being evaluated for potential admission Previous use of drugs that may be active against COVID‐19 in the eyes of the investigators Participant has any abnormal laboratory test results at screening Participantis using adrenocorticosteroids Participant has a serious chronic disease (e.g. uncontrolled HIV, cancer requiring chemotherapy within the preceding 6 months, and/or moderate or severe hepatic insufficiency) Has renal insufficiency requiring haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) Has liver impairment greater than Child Pugh A History of alcohol or drug abuse in the previous 6 months, psychiatric disease that is not well controlled Has taken another investigational drug within the past 30 days Is deemed by the Investigator to be ineligible for any reason
Interventions	Intervention Acebilustat (100 mg capsule administered orally once daily ) Camostat (200 mg tablet administered orally 4 times daily ) Comparator Placebo
Outcomes	Efficacy outcomes All‐cause mortality at up to 30 days: planned at up to 60 days: not planned Clinical progression/improvement of symptoms: planned Admission to hospital: planned Length of hospital stay: planned Admission to ICU: not planned Length of ICU stay: not planned Quality of life, including fatigue: not planned Viral clearance: planned Safety outcomes Number of participants with grade 3 and grade 4 AEs: not planned Number of participants with SAEs: not planned Additional study outcomes Time from randomisation to sustained symptom resolution assessed over a 28‐day period Time to first resolution Indicator participant has developed antibodies to SARS‐CoV‐2
Notes	Funding: Stanford University